MenaQ7® Verified by the Non-GMO Project

OSLO, NORWAY and METUCHEN, NJ (6 April 2016) – NattoPharma is proud to announce
that its complete line of MenaQ7® Vitamin K2 as MK-7 has received verification
from the Non-GMO Project, a non-profit 501(c)3 organization that offers North
America’s only third party verification and labeling for non-GMO (genetically
modified organism) food and products.

“MenaQ7 has always been non-GMO, yet obtaining Non-GMO Project verification
helps reinforce our commitment to our partners, who seek to offer the safest,
healthiest finished products available,” says Eric Anderson, senior vice
president of global sales and marketing with NattoPharma.

“Consumers are actively seeking out non-GMO products, so having the Non-GMO
Project verify our line in accordance with their standard provides our partners
an added level of support they rightfully expect,” Anderson continues. “Further,
it perpetuates MenaQ7’s reputation as being the leading Vitamin K2 as MK-7
brand.”

For more information, visit http://www.nongmoproject.org/find-non-gmo/search
-participating-products/search/?brandId=9496.

# # #

About MenaQ7®

MenaQ7® is the best documented, commercially available vitamin K2 as MK-7 with
guaranteed actives and stability, clinical substantiation, and international
patents granted and pending. MenaQ7® is available in two varieties: natural
vitamin K2 as MK-7 Crystals and nature-identical synthetic vitamin K2 as MK-7
PURE. For more information on the health benefits of MenaQ7, visit menaq7.com.

About NattoPharma

NattoPharma ASA, based in Norway, is the  world’s leader in vitamin K2 research
and development. NattoPharma is the exclusive international supplier of MenaQ7®
Vitamin K2 as MK-7, and has a multi-year research and development program to
substantiate and discover the health benefits of vitamin K2 for applications in
the marketplace for functional food and dietary supplements. With a global
presence, the company established its North American subsidiary, NattoPahrma
USA, Inc., in Meuchen, NJ. For more information, visit nattopharma.com.

For more information, please contact:

Kate Quackenbush, Director of Communications

NattoPharma USA, Inc.

Phone: +1 609-643-0749

E-mail: kate.quackenbush@nattopharma.com